Recommended

Resilient supply: safeguarding Europe’s generics
Sanofi’s ‘factory of the future’ vision
AI Act: data governance and compliance implications
mRNA vaccine research cut by RFK Jr
EU Biotech Act public consultation opens
FDA PreCheck programme encourages new manufacturing sites
President Trump targets US pharma supply chain resilience
CDMO Ofichem acquires Uppsala site from Meribel
webinar

Quality assessment of biologics: higher order structure analysis using NMR

Supported by:

27 September 2018

16
SHARES

Bruker WebinarThe webinar describes how 2D NMR can offer protein biochemists unprecedented analytical precision. By assigning just one spectrum, users can obtain a unique fingerprint of a protein at an atomistic resolution. This non-destructive technique can also be combined with other complimentary techniques to gain even further insights into sample quality.

Examples of the spectral processing and statistical and chemometric analysis methods being developed to increase automation is also described. Aside from enabling simultaneous analysis of large data volumes, the automation available today has almost advanced to the point that even non-experts will be able to acquire and analyse NMR spectra for decision making.

You will also learn: 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

  • 2D NMR spectral fingerprinting for higher order structure analysis of biologics
  • Application to biologics in their formulated state for structural assessment
  • Benefits of the advances in automated data acquisition and analysis
  • Reproducibility and robustness for inter-lab precision
  • Practical, easy application of 2D NMR in the biopharma spa
  • Bruker’s latest instrumentation and software for 2D NMR analysis

Keynote Speakers

John MarinoJohn P. Marino, Leader, Biomolecular Structure & Function Group – NIST

Associate Director, Institute for Bioscience and Biotechnology Research

National Institute of Standards and Technology & University of Maryland

Since 2008, Dr. Marino has been the leader of the NIST Biomolecular Structure & Function Group and Associate Director of the Institute for Bioscience and Biotechnology Research (IBBR), a joint research institute of the University of Maryland and NIST, in Rockville, Maryland. 

Dr. Marino joined NIST in 1997 as a Research Chemist and was appointed Adjunct Professor at the University of Maryland.  Prior to coming to NIST, Dr. Marino completed a Ph.D. in Chemistry from Yale University in 1995 and a two year postdoc at the Goethe Universität in Frankfurt, Germany as an Alexander von Humboldt fellow.  Dr. Marino’s research interests are primarily focused on developing Nuclear Magnetic Resonance (NMR) methods to advance precision measurement of biomolecular structure and dynamics, with his most recent work focused on the development of techniques for assessment of the higher-order-structure (HOS) of biotherapeutics. 

Jason Wood Jason S. Wood, Ph.D. Americas Market Manager – Pharma/Biotech 

With a Ph.D. in Bio-organic Chemistry (University of Buffalo) and a post-doctoral fellowship at the National Institutes of Health (NIA), Dr. Wood spent a number of years in the biopharmaceutical industry before becoming the Global Product Line Manager of Quadrupole Mass Spectrometry at Varian Inc. Subsequently, Dr. Wood became Senior Product Manager of Bio IC at Dionex Corp (now Thermo Fisher Scientific), where is successfully released and managed the world’s first capillary ion chromatography system, the ICS-5000. Dr. Wood is currently the Regional Market Manager (Americas) at Bruker BioSpin where he manages marketing in the pharma and biotech space. 

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Share via
Share via